Difference between revisions of "IPH-2101"
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic") |
Warner-admin (talk | contribs) |
||
(6 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells with their ligands. | + | Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells with their ligands. It is hypothesized that by blocking these inhibitory signals, there will be enhanced activation of NK cells and tumor cell destruction.<ref>[http://www.innate-pharma.com/candidate/iph-2101 Innate Pharma's IPH 2101 (Anti-KIR) site]</ref><ref>[http://www.innate-pharma.com/mabs-targeting-nk-cells Information from Innate Pharma about monoclonal antibodies targeting NK cells]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Line 8: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
No information available. | No information available. | ||
− | + | ==Also known as== | |
+ | *'''Code name:''' 1-7F9 | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
− | + | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | |||
− | |||
[[Category:Anti-KIR antibodies]] | [[Category:Anti-KIR antibodies]] | ||
− | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 00:33, 29 July 2023
General information
Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells with their ligands. It is hypothesized that by blocking these inhibitory signals, there will be enhanced activation of NK cells and tumor cell destruction.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.
Also known as
- Code name: 1-7F9